share_log

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

《每日生物技術脈搏》:布里斯托爾·邁爾斯、BridgeBio 簽署腫瘤學協議、FDA 點頭支持Lava Therapeutics血液癌研究等
Benzinga Real-time News ·  2022/05/12 20:49
Here's a roundup of top developments in the biotech space over the last 24 hours:
以下是過去 24 小時內生物技術領域的主要進展摘要:
Stocks In Focus
焦點股票
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
BridgeBio與Bristol Myers簽署了腫瘤學SHP2抑制劑的許可協議
BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398 in oncology. 
布里奇生物製藥公司(納斯達克股票代碼:BBIO)宣佈了獨家許可布里斯托爾邁爾斯施貴寶公司紐約證券交易所代碼:BMY)將在腫瘤學領域開發和商業化 BBP-398。
BridgeBio will receive an upfront payment of $90 million, up to $815 million in milestone payments and tiered royalties in the low- to mid-teens. 
BridgeBio將獲得9000萬美元的預付款、高達8.15億美元的里程碑付款和低到中期的分級特許權使用費。
BridgeBio will retain the option to acquire higher royalties in the U.S. in connection with funding a portion of development costs upon the...
BridgeBio將保留在美國獲得更高特許權使用...

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論